Proactive Investors - Run By Investors For Investors

Proteomics International Laboratories boosts balance sheet with sale of CPR Pharm Services stake

An MOU between the two companies targeting advanced diagnostics and analytical services for clinical trials remains in place.
Laboratory work
The medical technology company has received $928,399 for the sale

Proteomics International Laboratories Ltd (ASX:PIQ) has boosted its balance sheet with the sale of its shareholding in CPR Pharma Services Pty Ltd for total consideration of $928,399.

The medical technology company has been advised that an offer to purchase all the shares of CPR has been received and accepted by CPR’s majority shareholder.

Sale due to settle later this month

This sale is due to settle on or about September 30, 2018.

In March 2018 Proteomics issued more than 3.868 million ordinary shares at a deemed issue price of 30.45 cents to acquire 10% of the fully diluted issued share capital of CPR.

The sale, therefore, equates to receipt of 24 cents per PIQ share issued with shares currently trading at around 26 cents.

MOU remains in place

An MOU between Proteomics and CPR remains in place, targeting advanced diagnostics and analytical services for clinical trials.

Proteomics International, which operates from state-of-the-art facilities on Perth’s QEII Medical Campus, is at the forefront of predictive diagnostics and bioanalytical services.

It specialises in the area of proteomics – the industrial scale study of the structure and function of proteins.

View full PIQ profile View Profile

Proteomics International Laboratories Ltd Timeline

Related Articles

word cancer under magnifying glass
May 02 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use